Catheter Related InfectionPhase 4CITRIMNCT02563041
Comparative Effectiveness of 30%TSC and Heparin Lock Solution in Hemodialysis Catheters
A Phase 4 study testing 30% TSC and Heparin in people with Catheter Related Infection, run by Catholic University of Pelotas.
Trial summary
BACKGROUND: Central venous catheters (CVC) are the only option when hemodialysis is needed for patients without definitive vascular access. However, CVC use is associated with complications such as infection, thrombosis, and dysfunction, leading to higher mortality and expenditures. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Catheter Related Infection
- What is being tested?
- 30% TSC and Heparin
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 179 participants
- Where
- No sites listed yet
- Study dates
- Jul 2012to Jul 2014
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- patients older than 18 years and
- with chronic or acute renal failure and
- requiring hemodialysis through a catheter.
Who cannot join
- patients admitted to the intensive care ward,
- receiving a tunneled catheter,
- patients with suspected heparin-induced thrombocytopenia,
- patients with allergy to heparin or TSC30%,
- patients with systemic or localized infection
- pregnant women
About this study
Official title: Comparative Effectiveness of 30% Trisodium Citrate and Heparin Lock Solutions in Preventing Infection and Dysfunction of Hemodialysis Catheters: a Randomized Controlled Trial (CITRIM Trial)
BACKGROUND: Central venous catheters (CVC) are the only option when hemodialysis is needed for patients without definitive vascular access. However, CVC use is associated with complications such as infection, thrombosis, and dysfunction, leading to higher mortality and expenditures. The aim of this study was to compare the effectiveness of 30% trisodium citrate (TSC30%) with heparin as CVC lock solution in preventing catheter-related bloodstream infections (CRBSI) and dysfunction in hemodialysis patients. METHODS: Randomized, double-blind controlled trial comparing the event-free survival of non-tunneled CVC locked with heparin or TSC30% in adult hemodialysis patients.
Read the detailed description
METHODS Study Design This double blind randomized controlled trial (RCT) was conducted from July 2012 until July 2014 in the dialysis and transplantation unit of a Brazilian university hospital. The patients were randomly assigned to have their catheter locked with either unfractionated sodium heparin 5000 U/mL or 30% trisodium citrate. The randomization was performed through a computer-generated list of random numbers in blocks of six. Patients and investigators were unaware of the treatment assignments. Allocation concealment was performed using opaque, sealed envelopes for assignment.
After each hemodialysis (HD) session, patients assigned to 30%TSC had their catheter lumens flushed with 0.9% sodium chloride and locked with a volume of 30% TSC solution equivalent to the catheter internal lumen. Patients assigned to heparin had their catheter lumens flushed with 0.9% sodium chloride and locked with a volume of 5000 U/mL heparin equivalent to CVC internal lumen. Catheter care was according to international guidelines, including strict asepsis on insertion and exit-site dressing changes after each HD session by staff wearing masks and sterile gloves.
SELECTION OF PATIENTS Patients were eligible for enrollment in the RCT when they were older than 18 years and had chronic or acute renal failure that required hemodialysis through a catheter. Patients admitted to the intensive care ward, receiving a tunneled catheter, with suspected heparin-induced thrombocytopenia, allergy to heparin or TSC30%, with systemic or localized infection or pregnant women were excluded. The site of insertion and specific type of catheter were decided by the interventionist physician.
MAIN OUTCOMES Catheter related bloodstream infection (CRBSI): CRBSI was defined as fever and/or chills during a dialysis session and at least one positive blood culture, with no other obvious cause of infection after careful clinical examination. The management of the CRBSI was performed according to guidelines. Empirical antibiotic therapy was immediately given. The catheter was removed if there was isolation of S. aureus or fungus, or there was no clinical recovery within 48 hours of antibiotic treatment.
Catheter dysfunction: Dysfunction was defined as a persistent inability to obtain a blood flow above 200 mL/min. In this situation, the catheter was removed or exchanged over guidewire.
OTHER PREDICTORS Patients-related: Data was also collected about age, gender, skin color, presence of diabetes, diagnosis of CKD or acute kidney injury, and hemodialysis vintage.
Catheter-related: Site of insertion (jugular, subclavian or femoral vein), and ordinal number of catheter in the same patient (considering only the study period).
STATISTICAL ANALYSIS Calculation of the required sample size was based on main outcomes. It was assumed that the group with heparin lock would have a rate of catheter-related bloodstream infection of 150% greater than that of catheters with TCS30% lock. With a two-sided test, and an alfa error of 5% and 80% of power, it was required 112 catheters for each group.
The primary analysis was made through survival analysis with Cox proportional hazard regression. Initially the investigators proceed to univariate analysis using Kaplan-Meier curves and log rank test for the categorical variables, and univariate Cox regression for continuous variables. The predictors which have a p-value lower than 0.25 in univariate analysis were included in final model. Interactions were checked for any possible association of predictors. The likelihood ratio test was used for compare nested with full models. The proportionality of predictors was verified by introduction of time-dependent variables in the model. If any predictor violates the proportionality assumption, the analysis would be stratified for that predictor. Well-functioning catheters at the end of the study period, catheters removed because patients acquired functional arteriovenous fistula, renal function recovery, changed to peritoneal dialysis or had transplantation were analyzed as censored data. The analysis was all done on intention-to-treat base. All reported p-value are two sided. The analysis was performed using the STATA 11.2 statistical software (Stata Corporation, College Station, TX, USA)
ETHICAL ASPECTS The study protocol was approved by the local review board. Written informed consent was obtained from all patients before enrollment.
- Conditions
- Catheter Related Infection
- Being tested
- 30% TSC, Heparin
- Medical subject headings
- Catheter-Related Infections
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
30% TSCDrug
Also called 30% trisodium citrate
The patients were randomly assigned to have their catheter locked with either unfractionated sodium heparin 5000 U/mL or 30% trisodium citrate.
HeparinDrug
Also called unfractionated sodium heparin 5000 U/mL
The patients were randomly assigned to have their catheter locked with either unfractionated sodium heparin 5000 U/mL or 30% trisodium citrate.
| Study group | Role | What they receive |
|---|---|---|
| 30%TSC | Experimental | After each hemodialysis (HD) session, the catheter lumens were flushed with 0.9% sodium chloride and locked with a volume of 30%TSC solution exactly equivalent to the catheter internal lumen. Receives: Drug: 30% TSC |
| Heparin 5000 U/mL | Active comparator | After each hemodialysis (HD) session, the catheter lumens were flushed with 0.9% sodium chloride and locked with a volume of unfractionated sodium heparin 5000 U/mL solution exactly equivalent to the catheter internal lumen. Receives: Drug: Heparin |
What is being measured
The primary outcome is the main question the study is designed to answer.
Catheter related bloodstream infection
Measured: through study completion, an average of 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Sep 2015 (estimated)
- Study startJul 2012
- Primary completionJul 2014
- Study completionJul 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Catheter Related InfectionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 179 participants (actual)
Sponsor and investigators
- Lead sponsor
- Catholic University of Pelotas
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Maristela Bohlke, Catholic University of Pelotas
- Investigators
- Maristela Bohlke, MD, PhD, Principal investigator, Catholic University of Pelotas
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02563041
- Sponsor's protocol ID
- UCPel
- Acronym
- CITRIM
- Status last verified
- Sep 2015
- First submitted
- 23 Sep 2015
- Last updated
- 29 Sep 2015
- Results posted
- No
- Data monitoring committee
- No
Publications
Correa Barcellos F, Pereira Nunes B, Jorge Valle L, Lopes T, Orlando B, Scherer C, Nunes M, Araujo Duarte G, Bohlke M. Comparative effectiveness of 30 % trisodium citrate and heparin lock solution in preventing infection and dysfunction of hemodialysis catheters: a randomized controlled trial (CITRIM trial). Infection. 2017 Apr;45(2):139-145. doi: 10.1007/s15010-016-0929-4. Epub 2016 Aug 29.
PubMed 27573387
Study at a glance
From the registry record, last updated by the sponsor on 29 Sep 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparative Effectiveness of 30% Trisodium Citrate and Heparin Lock Solutions in Preventing Infection and Dysfunction of Hemodialysis Catheters: a Randomized Controlled Trial (CITRIM Trial)
- ClinicalTrials.gov ID
- NCT02563041
- Acronym / sponsor ID
- CITRIM / UCPel
- Conditions
- Catheter Related Infection
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 179 participants (actual)
- Lead sponsor
- Catholic University of PelotasUniversity, hospital or other
- Study start
- Jul 2012
- Primary completion
- Jul 2014 (actual)
- Study completion
- Jul 2014 (actual)
- First posted
- 29 Sep 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
BACKGROUND: Central venous catheters (CVC) are the only option when hemodialysis is needed for patients without definitive vascular access. However, CVC use is associated with complications such as infection, thrombosis, and dysfunction, leading to higher mortality and expenditures. The aim of this study was to compare the effectiveness of 30% trisodium citrate (TSC30%) with heparin as CVC lock solution in preventing catheter-related bloodstream infections (CRBSI) and dysfunction in hemodialysis patients. METHODS: Randomized, double-blind controlled trial comparing the event-free survival of non-tunneled CVC locked with heparin or TSC30% in adult hemodialysis patients.
Detailed description
METHODS Study Design This double blind randomized controlled trial (RCT) was conducted from July 2012 until July 2014 in the dialysis and transplantation unit of a Brazilian university hospital. The patients were randomly assigned to have their catheter locked with either unfractionated sodium heparin 5000 U/mL or 30% trisodium citrate. The randomization was performed through a computer-generated list of random numbers in blocks of six. Patients and investigators were unaware of the treatment assignments. Allocation concealment was performed using opaque, sealed envelopes for assignment.
After each hemodialysis (HD) session, patients assigned to 30%TSC had their catheter lumens flushed with 0.9% sodium chloride and locked with a volume of 30% TSC solution equivalent to the catheter internal lumen. Patients assigned to heparin had their catheter lumens flushed with 0.9% sodium chloride and locked with a volume of 5000 U/mL heparin equivalent to CVC internal lumen. Catheter care was according to international guidelines, including strict asepsis on insertion and exit-site dressing changes after each HD session by staff wearing masks and sterile gloves.
SELECTION OF PATIENTS Patients were eligible for enrollment in the RCT when they were older than 18 years and had chronic or acute renal failure that required hemodialysis through a catheter. Patients admitted to the intensive care ward, receiving a tunneled catheter, with suspected heparin-induced thrombocytopenia, allergy to heparin or TSC30%, with systemic or localized infection or pregnant women were excluded. The site of insertion and specific type of catheter were decided by the interventionist physician.
MAIN OUTCOMES Catheter related bloodstream infection (CRBSI): CRBSI was defined as fever and/or chills during a dialysis session and at least one positive blood culture, with no other obvious cause of infection after careful clinical examination. The management of the CRBSI was performed according to guidelines. Empirical antibiotic therapy was immediately given. The catheter was removed if there was isolation of S. aureus or fungus, or there was no clinical recovery within 48 hours of antibiotic treatment.
Catheter dysfunction: Dysfunction was defined as a persistent inability to obtain a blood flow above 200 mL/min. In this situation, the catheter was removed or exchanged over guidewire.
OTHER PREDICTORS Patients-related: Data was also collected about age, gender, skin color, presence of diabetes, diagnosis of CKD or acute kidney injury, and hemodialysis vintage.
Catheter-related: Site of insertion (jugular, subclavian or femoral vein), and ordinal number of catheter in the same patient (considering only the study period).
STATISTICAL ANALYSIS Calculation of the required sample size was based on main outcomes. It was assumed that the group with heparin lock would have a rate of catheter-related bloodstream infection of 150% greater than that of catheters with TCS30% lock. With a two-sided test, and an alfa error of 5% and 80% of power, it was required 112 catheters for each group.
The primary analysis was made through survival analysis with Cox proportional hazard regression. Initially the investigators proceed to univariate analysis using Kaplan-Meier curves and log rank test for the categorical variables, and univariate Cox regression for continuous variables. The predictors which have a p-value lower than 0.25 in univariate analysis were included in final model. Interactions were checked for any possible association of predictors. The likelihood ratio test was used for compare nested with full models. The proportionality of predictors was verified by introduction of time-dependent variables in the model. If any predictor violates the proportionality assumption, the analysis would be stratified for that predictor. Well-functioning catheters at the end of the study period, catheters removed because patients acquired functional arteriovenous fistula, renal function recovery, changed to peritoneal dialysis or had transplantation were analyzed as censored data. The analysis was all done on intention-to-treat base. All reported p-value are two sided. The analysis was performed using the STATA 11.2 statistical software (Stata Corporation, College Station, TX, USA)
ETHICAL ASPECTS The study protocol was approved by the local review board. Written informed consent was obtained from all patients before enrollment.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| 30%TSC | Experimental | Drug: 30% TSCAfter each hemodialysis (HD) session, the catheter lumens were flushed with 0.9% sodium chloride and locked with a volume of 30%TSC solution exactly equivalent to the catheter internal lumen. |
| Heparin 5000 U/mL | Active comparator | Drug: HeparinAfter each hemodialysis (HD) session, the catheter lumens were flushed with 0.9% sodium chloride and locked with a volume of unfractionated sodium heparin 5000 U/mL solution exactly equivalent to the catheter internal lumen. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- patients older than 18 years and
- with chronic or acute renal failure and
- requiring hemodialysis through a catheter.
Key exclusion criteria (6 listed)
- patients admitted to the intensive care ward,
- receiving a tunneled catheter,
- patients with suspected heparin-induced thrombocytopenia,
- patients with allergy to heparin or TSC30%,
- patients with systemic or localized infection
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| 30% TSCAlso: 30% trisodium citrateThe patients were randomly assigned to have their catheter locked with either unfractionated sodium heparin 5000 U/mL or 30% trisodium citrate. | Drug | 30%TSC |
| HeparinAlso: unfractionated sodium heparin 5000 U/mLThe patients were randomly assigned to have their catheter locked with either unfractionated sodium heparin 5000 U/mL or 30% trisodium citrate. | Drug | Heparin 5000 U/mL |
Primary outcome
Catheter related bloodstream infection
Time frame: through study completion, an average of 2 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Sep 2015.
- Derived from this study: PubMed 27573387Correa Barcellos F, Pereira Nunes B, Jorge Valle L, Lopes T, Orlando B, Scherer C, Nunes M, Araujo Duarte G, Bohlke M. Comparative effectiveness of 30 % trisodium citrate and heparin lock solution in preventing infection and dysfunction of hemodialysis catheters: a randomized controlled trial (CITRIM trial). Infection. 2017 Apr;45(2):139-145. doi: 10.1007/s15010-016-0929-4. Epub 2016 Aug 29.
Related trials for Catheter Related Infection
Not yet recruitingObservational study
Novel Antimicrobial Solution to Prevent Infections
Kidney Stone, Infection
RecruitingPhase 4
Open-Label Study to Assess Safety and Time to Catheter-related Bloodstream Infections (CRBSI) in Subjects From Birth to < 18 Years of Age
Catheter-Related Infections
Recruiting
Effectiveness of the NowCath Foley in Reducing Catheter-Associated UTIs and Blockages in Long-Term Indwelling Catheter Users (REDUCE)
Urinary Catheters, Urinary Catheterization
Not yet recruitingObservational study
Efficacy and Safety of Peripherally Inserted Central Venous Catheters
Critical Illness, Catheter-Related Infections
RecruitingPhase 4
Secondary Prevention of VTE in Patients With Cancer and Catheter-Related Upper Extremity Deep Vein Thrombosis
Venous Thromboembolism, Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Maristela Bohlke, MD, PhD principal investigator
Catholic University of Pelotas
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing 30% TSC and Heparin in people with Catheter Related Infection, run by Catholic University of Pelotas.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 29 Sep 2015. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Catheter related bloodstream infection (time frame: through study completion, an average of 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02563041, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Sep 2015.